Fotemustene (CAS 92118-27-9)
QUICK LINKS
Fotemustene is a compound that has been the focus of research due to its alkylating properties, which are of interest in the study of chemical interactions with nucleophilic sites in biomolecules. Researchers utilize fotemustene to understand the mechanisms of alkylation and the subsequent effects on molecular stability and function. In the field of synthetic chemistry, fotemustene is involved in studies aiming to elucidate the structure-activity relationships of alkylating agents. Its behavior in various solvents and conditions is also investigated to improve the handling and application of such compounds in a laboratory setting. Additionally, fotemustene is used as a reference compound in the development of new chemical entities with potential for various applications, given its structural features and reactivity profile.
Fotemustene (CAS 92118-27-9) References
- Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. | Khayat, D., et al. 1992. Melanoma Res. 2: 147-51. PMID: 1450667
- Focus on Fotemustine. | De Rossi, A., et al. 2006. J Exp Clin Cancer Res. 25: 461-8. PMID: 17310834
- Temozolomide in combination with fotemustine in patients with metastatic melanoma. | Tas, F., et al. 2008. Cancer Chemother Pharmacol. 62: 293-8. PMID: 17909803
- Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. | Khayat, D., et al. 1991. Am J Clin Oncol. 14: 400-4. PMID: 1951178
- [Fotemustine, a new nitrosourea derivative. Current status of development]. | Cour, V. and Langenbahn, H. 1990. Onkologie. 13: 7-11. PMID: 2186326
- Fotemustine for the treatment of melanoma. | Quéreux, G. and Dréno, B. 2011. Expert Opin Pharmacother. 12: 2891-904. PMID: 22077794
- Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. | Addeo, R., et al. 2013. Expert Opin Drug Saf. 12: 729-40. PMID: 23560594
- An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. | Lombardi, G., et al. 2014. Biomed Res Int. 2014: 698542. PMID: 24800248
- Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis. | Genovese, T., et al. 2021. Int J Mol Sci. 22: PMID: 34206129
- Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. | McBain, C., et al. 2021. Cochrane Database Syst Rev. 5: CD013579. PMID: 34559423
- Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. | Wu, J., et al. 2021. Cancer Biol Med. 19: 1089-99. PMID: 34633776
- Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma. | Lin, M., et al. 2023. Leuk Lymphoma. 64: 605-612. PMID: 36657436
- Fotemustine in the treatment of brain primary tumors and metastases. | Khayat, D., et al. 1994. Cancer Invest. 12: 414-20. PMID: 8032964
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fotemustene, 5 mg | sc-205703 | 5 mg | $100.00 | |||
Fotemustene, 25 mg | sc-205703A | 25 mg | $225.00 |